The mCSPC products in the development include Nubeqa (Bayer), Keytruda (Merck Sharp & Dohme), Talazoparib (Pfizer), Niraparib (Janssen), Rubraca (Clovis Oncology), Opdivo (Bristol-Myers Squibb), Capivasertib (AstraZeneca), 177Lu-PSMA-617 (Novartis), Firmagon (Ferring Pharmaceuticals), Tecentriq (Genentech), Cabometyx (Exelixis/ Bristol-Myers Squibb), and others.